Exelixis, Inc. (Nasdaq: EXEL) today announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Exelixis (EXEL) PT Raised to $33 at Needham & CompanyFebruary 13, 2019 10:52 AM Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q February 13, 2019 10:01 AM Exelixis (EXEL) PT Lowered to $31 at OppenheimerFebruary 13, 2019 7:58 AM Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery EffortsFebruary 12, 2019 4:05 PM